MNPR (Monopar Therapeutics) Total Long-Term Assets : $0.00 Mil (As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Monopar Therapeutics Total Long-Term Assets?

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Monopar Therapeutics's Total Long-Term Assets for the quarter that ended in Sep. 2024 was $0.00 Mil.

Monopar Therapeutics Total Long-Term Assets Historical Data

The historical data trend for Monopar Therapeutics's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Monopar Therapeutics Total Long-Term Assets Chart

Monopar Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Long-Term Assets

Get a 7-Day Free Trial

0.12

0.07

0.06

0.01

Monopar Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Long-Term Assets	Get a 7-Day Free Trial															0.03	0.01	-	-	-

Monopar Therapeutics Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Monopar Therapeutics Total Long-Term Assets Related Terms

Thank you for viewing the detailed overview of Monopar Therapeutics's Total Long-Term Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Monopar Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Monopar Therapeutics Inc (NAS:MNPR) » Definitions » Total Long-Term Assets

Comparable Companies

Traded in Other Exchanges

1IY0:Germany

Address

1000 Skokie Boulevard, Suite 350, Wilmette, IL, USA, 60091

Website

https://www.monopartx.com

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of?Validive?for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin?for the treatment?of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

Executives

Andrew Cittadine	officer: Chief Operating Officer	C/O 1000 SKOKIE BLVD SUITE 350, WILMETTE IL 60091
Michael J Brown	director	C/O EURONET WORLDWIDE, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 300, LEAWOOD KS 66211
Arthur J Klausner	director	ONE PALMER SQUARE, PRINCETON NJ 08542
Raymond Anderson	director	C/O MONOPAR THERAPEUTICS INC., 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Kim R Tsuchimoto	officer: Chief Financial Officer	C/O MONOPAR THERAPEUTICS INC., 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Chandler Robinson	director, officer: Chief Executive Officer	C/O SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Patrice Rioux	other: Acting Chief Medical Officer	C/O MONOPAR THERAPEUTICS INC, 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Christopher M Starr	director	C/O MONOPAR THERAPEUTICS INC, 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Filho Jose Octavio Pinto Costa	officer: Chief Medical Officer	C/O 1000 SKOKIE BLVD SUITE 350, WILMETTE IL 60091
Tactic Pharma Llc	10 percent owner	C/O SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Diane Hendricks	10 percent owner	C/O GEM PHARMACEUTICALS, 200 RANDOLPH AVE., HUNTSVILLE AL 35801
Karl Leo	10 percent owner	C/O GEM PHARMACEUTICALS, 200 RANDOLPH AVE., HUNTSVILLE AL 35801
Kirsten Anderson	officer: SVP, Clinical Development	C/O SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Gem Pharmaceuticals Llc	10 percent owner	C/O 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Tacticgem Llc	10 percent owner	1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091